Novel Pacemaker Provides Adaptive Therapeutic Response

An innovative cardiac resynchronization therapy (CRT) pacemaker offers improved therapeutic options that meet the widest range of patient needs.

The Biotronik Evia HF-T Pacemaker is a triple-chamber CRT device that offers closed loop stimulation (CLS) technology, a rate response algorithm that responds to exercise and acute mental stress on a beat-to-beat basis. Among the other features of the device are tools to continuously maximize CRT therapy, features to optimize left ventricular (LV) thresholds and avoid phrenic nerve stimulation, information to help manage a patient’s heart failure (HF) progression, and unique technologies that provide a wide choice of capture control and LV pacing polarities as part of a range of solutions for continuous, effective, biventricular pacing without complications.


The Evia HF-T system also includes innovative home monitoring technology--with several parameters available for customizable alert settings--which automatically transmits a patient’s clinical and device status on a daily basis, making it readily available to the physician for early detection of clinically relevant events, without the need for any patient interaction. One of the important indicators measured is thoracic impedance (TI), which measures increased lung fluid levels, an indicator of HF progression. The Biotronik Evia HF-T Pacemaker is a product of Biotronik (Berlin, Germany), and has been approved by the US Food and Drug Administration (FDA).

“Electrophysiologists ranging from private practice to academic training centers agree that Biotronik’s Evia HF-T offers groundbreaking technology, which makes it an ideal option for patients with heart failure conditions,” said Rex Richmond, vice president of marketing at Biotronik. “Evia HF-T is the only CRT pacemaker to offer all the therapeutic benefits available in competing CRT pacemakers - plus unique technology, such as cellular home monitoring with no cost to the patient.”

“For me, this device means my options for using CLS - a therapy that is both much needed and well documented in my clinical practice - are expanded to include patients with heart failure,” said Blair Grubb, MD, from the University of Toledo (OH, USA). “Patients in general can, and do benefit from this unique physiologic rate-adaptive pacing mode, but patients with heart failure may derive unique benefit since adaptive algorithms dependent on physical activity alone may not respond as appropriately.”

Related Links:
Biotronik